Where is ALMIRALL S.P.A headquartered?

Almirall, S.A. is recorded with headquarters in Barcelona, IT in NovaPharmaNews public regulatory and sponsor datasets.

Is ALMIRALL S.P.A publicly traded?

ALMIRALL S.P.A is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with ALMIRALL S.P.A?

We link 6 drug profile(s) where ALMIRALL S.P.A appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is ALMIRALL S.P.A sponsoring?

ALMIRALL S.P.A is linked to 11 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list ALMIRALL S.P.A as applicant?

308 USPTO PatentsView record(s) name Almirall, S.A. or a normalized variant as applicant.

What pipeline phases does ALMIRALL S.P.A have in our database?

Phase distribution from linked programs: approved: 4, phase 3: 3, phase 2: 3, phase 1: 1.

How many US-approved drugs are linked to ALMIRALL S.P.A?

6 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does ALMIRALL S.P.A hold EU marketing authorisations in our data?

1 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on ALMIRALL S.P.A?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is ALMIRALL S.P.A data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

ALMIRALL S.P.A Pharmaceuticals Company Profile

Name: ALMIRALL S.P.A intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona
Employees: 2
Programs: 11
Drugs: 20
Patents: 308

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

ALMIRALL S.P.A is a pharma organization headquartered in Barcelona, IT. Primary therapeutic focus areas include Recurrent Respiratory Tract Infections, Actinic Keratosis on the Face or Scalp, Alopecia areata, Actinic Keratosis, moderate-to-severe hidradenitis suppurativa. NovaPharmaNews links 11 clinical program(s), 6 drug profile(s), and 308 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (4), phase 3 (3), phase 2 (3).

Company snapshot

Almirall is a global biopharmaceutical company focused on medical dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our purpose is at the core of our work: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”. Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop a

7 approved product(s) across US/EU regulatory metadata.
11 active pipeline program(s) linked via ClinicalTrials.gov.
308 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for ALMIRALL S.P.A. Not investment advice.

Top assets

View drugs (20) View projects (11)

Lead pipeline drugs

abacavir, dolutegravir, lamivudine
approved
adalimumab
approved
azelaic acid
approved
chloride
Marketed / approved

Active clinical programs

M-14867-33 Actinic Keratosis on the Face or Scalp
Phase 3
M-17923-34 Atopic Dermatitis
Phase 3
M-27501-30 Nummular Dermatitis
Phase 3
LAD328, SODIUM CHLORIDE moderate-to-severe hidradenitis suppurativa
Phase 2

Momentum

Proprietary activity score for ALMIRALL S.P.A.

1 active signal

13 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 2 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Eli Lilly and

TA overlap score 32.4

Recent activity

Latest pipeline, patent, and corporate events for ALMIRALL S.P.A.

Jun 8, 2026 Clinical update
M-27501-30 — Phase 3
Jun 8, 2026 Clinical update
M-17923-34 — Phase 3
Jun 8, 2026 Clinical update
M-14867-33 — Phase 3
Jun 8, 2026 Clinical update
M-27312-01 — Phase 1
Jun 8, 2026 Clinical update
M-27134-10 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is ALMIRALL S.P.A?

ALMIRALL S.P.A is a pharma organization headquartered in Barcelona, IT. Primary therapeutic focus areas include Recurrent Respiratory Tract Infections, Actinic Keratosis on the Face or Scalp, Alopecia areata, Actinic Keratosis, moderate-to-severe hidradenitis suppurativa. NovaPha
Is ALMIRALL S.P.A publicly traded?

ALMIRALL S.P.A appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does ALMIRALL S.P.A develop or market?

We link 20 drug profile(s) where ALMIRALL S.P.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mira-pharmaceuticals-inc#company-drugs.
What are the latest developments for ALMIRALL S.P.A?

In the last 12 months our linked public records show 11 trial program update(s) and 10 US patent grant(s) tied to this profile.
What therapeutic areas does ALMIRALL S.P.A focus on?

ALMIRALL S.P.A focuses on Recurrent Respiratory Tract Infections, Actinic Keratosis on the Face or Scalp, Alopecia areata based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Infectious Disease

Cardiology

Immunology